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Severe human malaria is attributable to an excessive sequestration of Plasmodium falciparum–infected and uninfected
erythrocytes in vital organs. Strains of P. falciparum that form rosettes and employ heparan sulfate as a host receptor
are associated with development of severe forms of malaria. Heparin, which is similar to heparan sulfate in that it is
composed of the same building blocks, was previously used in the treatment of severe malaria, but it was discontinued
due to the occurrence of serious side effects such as intracranial bleedings. Here we report to have depolymerized
heparin by periodate treatment to generate novel glycans (dGAG) that lack anticoagulant-activity. The dGAGs disrupt
rosettes, inhibit merozoite invasion of erythrocytes and endothelial binding of P. falciparum–infected erythrocytes in
vitro, and reduce sequestration in in vivo models of severe malaria. An intravenous injection of dGAGs blocks up to
80% of infected erythrocytes from binding in the micro-vasculature of the rat and releases already sequestered
parasites into circulation. P. falciparum–infected human erythrocytes that sequester in the non-human primate Macaca
fascicularis were similarly found to be released in to the circulation upon a single injection of 500 lg of dGAG. We
suggest dGAGs to be promising candidates for adjunct therapy in severe malaria.
Citation: Vogt AM, Pettersson F, Moll K, Jonsson C, Normark J, et al. (2006) Release of sequestered malaria parasites upon injection of a glycosaminoglycan. PLoS Pathog 2(9):
e100. DOI: 10.1371/journal.ppat.0020100
Introduction
During Plasmodium falciparum malaria, signs of severe
anemia, respiratory distress, and cerebral malaria, or combi-
nations thereof, are common. These disease states are in part
a result of the excessive binding of P. falciparum–infected
erythrocytes (IE) to the vascular endothelium (cytoadher-
ence), and to infected and uninfected erythrocytes (rosetting,
giant-rosetting, and auto-agglutination). The sequestration
may lead to occlusion of the microvasculature, which thereby
contributes directly to the acute pathology of severe human
malaria [1–5].
The mechanisms behind sequestration of IE are to a large
degree dependent on the interaction between P. falciparum
erythrocyte membrane protein 1 (PfEMP1), a parasite-
derived molecule present at the surface of the IE [6,7], and
host receptors on endothelial and red blood cells [8–15].
PfEMP1 is composed of multiple cystein-rich extracellular
domains, which show afﬁnity for an array of host receptors
including the glycoasaminoglycan (GAG) heparan sulfate (HS)
[12,16–20]. The parasite employs HS during the adherence
both to the endothelium and to erythrocytes [12,16–20].
Binding to the HS receptor is mediated by the N-terminal
Duffy-binding-like domain 1a (DBL1a) of PfEMP1 in which
high-afﬁnity binding requires 12-mers of HS as well as the
presence of N-, 2-, and 6-O-sulfate groups [18,21]. HS and
heparin inhibit and reverse cytoadherence and rosetting of
laboratory strains and wild isolates in vitro [3,12,16–19].
Furthermore, the capacity of IE to adhere to HS is more
frequent in isolates of children with severe disease than in
those with mild malaria, suggesting HS to be one of the
sequestration receptors participating in the causation of
severe malaria [4].
Heparin, which is related to HS in that it is composed of
the same building blocks (glucosamine and glucuronic or
iduronic acid) and is negatively charged through sulfate
groups, was previously used in the adjunct treatment of
severe malaria with overall successful outcomes [22–26], but
its use was discontinued due to the occurrence of serious side
effects such as intracranial bleedings [27]. A rare pentameric
sequence present in standard heparin has high afﬁnity for
antithrombin III (AT) and is responsible for its anticoagulant
activity [28]. As heparin is known to be susceptible to selective
oxidation at this speciﬁc pentameric sequence [29], we
periodate-treated heparin, generating depolymerized glyco-
saminoglycans (dGAGs) that possess no anticoagulant activity,
but otherwise still is similar to HS/heparin. dGAGs are here
shown to have the same effect as heparin and HS in IE
adhesion experiments in vitro, and it is demonstrated to have
antisequestration effects in vivo, employing two newly
developed animal models in rats and monkeys.
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Generation and Evaluation of dGAG
Two batches of dGAGs (KI01 and DFX-101) were generated
by periodate treatment of heparin as described under
Materials and Methods; one batch (DFX-101) was created
under GMP conditions to allow administration to primates.
The preparations were evaluated as to anticoagulant activity
and the capacity to bind to live IE and to recombinant
PfEMP1. The anticoagulant activities of the two dGAG
preparations (KI01 and DFX-101), un-fractionated (standard)
heparin, AT afﬁnity–selected heparin (high and low AT–
afﬁnity fractions), and buffer, were evaluated using an APTT
(activated partial thromboplastin time) test. This test is
sensitive to factors XII, XI, IX, VIII, X, V, and II, but
insensitive to factors VII and XIII, and measures the overall
activity of the intrinsic coagulation system. Plasma samples
clotted within minutes after the addition of dGAG-KI01,
dGAG-DFX-101, low AT–afﬁnity heparin, or buffer, whereas
the samples did not clot even after 2 h if treated with
standard heparin or high AT–afﬁnity heparin (Table 1).
dGAG-KI01 was radiolabeled and further tested for bind-
ing to recombinant DBL1a, the known HS- and heparin-
binding domain of PfEMP1 [12,19], and for binding to live IE.
Recombinant DBL1a-GST fusion protein was expressed and
puriﬁed, and its binding capacity to
3H-labeled dGAG-KI01
was assessed in an in-solution assay. A jD of approximately 0.3
lM was estimated for the binding of dGAG-KI01 to DBL1a-
GST (Figure 1A), whereas no binding was seen to GST alone
(unpublished data). The results were conﬁrmed by letting the
dGAG interact with intact, live P. falciparum–infected eryth-
rocytes at the trophozoite stage in which the protein antigens
are presented at the cell surface with the native folding.
3H-
labeled dGAG-KI01 was incubated with IE of FCR3S1.2, of IE
from three recently established clinical isolates of Ugandan
children with severe malaria (UAS22, UAS29, and UAS31), or
with uninfected erythrocytes. Membranes and supernatants
were separated and analyzed for
3H-dGAG-KI01 by scintilla-
tion counting (see also [19]). dGAG-KI01 was demonstrated to
interact with the membranes of IE of the FCR3S1.2 and of the
Ugandan isolates UAS22, UAS29, and UAS3, but not with the
membranes of uninfected erythrocytes (Figure 1B).
3H-
dGAG-KI01 did not pass the erythrocyte membrane, whether
infected or not, as no
3H was found in any of the supernatants
(Figure 1B).
Effects of dGAGs on Rosetting and Cytoadherence In Vitro
Rosetting and cytoadherence of the highly rosetting and
multi-adhesive clone FCR3S1.2 are sensitive to heparin and
HS [12,16–20] as shown in Figure 2A–2C. FCR3S1.2 as well as
the UAS22, UAS29 and UAS31 clinical isolates were
furthermore tested for their sensitivity to dGAGs in rosetting
and cytoadherence assays. Both dGAG-KI01 and dGAG-DFX-
101 disrupted rosettes of all parasite cultures in a dose-
dependent manner and total or close to total disruption was
reached at 1 mg/ml with rosettes of FCR3S1.2 and UAS31
(Figure 3A and Figure S1). The rosettes of the clinical isolates
UAS22 and UAS29 were less sensitive to dGAG-KI01 and
dGAG-DFX-101 (Figure 3A and Figure S1).
The effect of dGAG-KI01 on the binding of IE to
cryosections of rat lung was evaluated by dynamic incubation
in order to mimic in vivo blood ﬂow conditions. The direct
effect on primary binding to rat lung sections was examined
by adding enriched IE together with dGAG simultaneously to
the lung sections (cytoadherence blocking). Up to 80% of the
binding of IE was blocked by dGAG-KI01 as compared with
untreated samples (Figure 3B). The blocking of binding of
FCR3S1.2 and UAS29 IE was less effective at concentrations
of 10 lg/ml than at 1 lg/ml. In order to test the efﬁciency of
the dGAGs to dislodge already bound IE from rat lung
sections, IE were allowed to adhere to the lung sections, and
unbound IE were washed off before incubation with the
dGAGs at different ﬁnal concentrations (cytoadherence
disruption). Cytoadherence disruption with dGAG-KI01
resulted in up to 100% reduction of binding (Figure 3C).
The effect of dGAG-DFX-101 was also evaluated and found to
be comparable to the effect of dGAG-KI01, both when
blocking or disrupting the cellular interactions (Figure S1).
Effects of dGAGs on Merozoite Invasion of Erythrocytes In
Vitro
Heparin has previously been demonstrated to inhibit
continuous cultivation of P. falciparum in vitro by blocking
merozoite invasion of erythrocytes [30–32]. dGAG-KI01,
dGAG-DFX101, standard heparin, chondroitin sulfate A
(CSA), and hyaluronic acid (HA) were therefore tested for
their blocking effects on merozoite invasion of erythrocytes
using an in vitro assay. dGAG–KI01 and dGAG-DFX-101
blocked merozoite invasion in a dose-dependent manner and
Table 1. Anticoagulant Activity of Different GAG-Preparations
Measured with APTT Test (Cephotest)
GAG Preparation Time to Induced Coagulation (min)
KI01 5.0
DFX-101 4.5
Low AT–affinity heparin 5.0
High AT–affinity heparin .120
Standard heparin .120
Buffer (PBS) 4.0
DOI: 10.1371/journal.ppat.0020100.t001
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Synopsis
Severe Plasmodium falciparum malaria is common and in part the
result of an excessive binding of infected erythrocytes in the
microvasculature. The parasite employs heparan sulfate during the
adherence to the vascular endothelium and to erythrocytes.
Heparin, which is related to heparan sulfate in that it is composed
of the same building blocks, was here periodate-treated to generate
depolymerized glycosaminoglycans (dGAGs) that possess no anti-
coagulant activity. The dGAGs disrupt erythrocyte and endothelial
binding of P. falciparum–infected erythrocytes in vitro. An intra-
venous injection of dGAGs blocks infected erythrocytes from
binding in the micro-vasculature of the rat and releases already
sequestrated parasites into circulation both in the rat and in a non-
human primate. If this approach is successfully translated to the
clinical setting, it may offer help to patients whereby the injection of
a dGAG releases already sequestered parasite-infected erythrocytes
and re-establishes the micro-vascular blood flow. The authors
suggest dGAGs to be promising candidates of adjunct therapy that
may have an important impact on malaria mortality.reached up to 83% and 86% inhibition, respectively (Figure 4
and Figure S2). The inhibitory effects of the dGAGs were
found to be equal to those of standard heparin (Figure 4).
CSA, which is similar to heparin and dGAG as it is a
negatively charged, sulfated molecule, and HA, a negatively
charged but non-sulfated molecule, showed only small effects
on merozoite invasion at the highest concentration tested
(41% and 40% inhibition, respectively), whereas there was no
effect at lower concentrations (Figure 4).
Effect of dGAGs on Sequestration of IE in Rats In Vivo
To evaluate whether the dGAGs were able to block and
reverse binding of IE in a more complex system, we explored
a recently developed animal model for studies of IE
sequestration, including both rosetting and cytoadherence
[33]. In this in vivo system it has been demonstrated that P.
falciparum–infected human erythrocytes of different strains
and clones robustly adhere in the rat lungs in a PfEMP1-
dependent manner [33]. Two different experimental set-ups
were used in which IE (FCR3S1.2) were either mixed with
dGAGs prior to injection into the rats in order to test the
effect on blocking primary binding (sequestration blocking)
or the dGAGs were injected after the establishment of IE-
sequestration (sequestration disruption). The sequestration
of IE in the lungs was 5.2% for FCR3S1.2 of the total amount
of material injected. The sequestration-blocking effect of the
dGAGs showed a complex but dose-dependent effect. The
best effect was seen with the intermediate quantity of dGAG-
KI01 showing an approximately 80% average reduction of
sequestration at 5-lg dGAG-KI01 injected/animal, whereas an
approximately 30% reduction of sequestration at 0.5 and 50
lg/animal and no, or almost no, effect at 0.05 and 500 lg/
animal were seen (Figure 5A and 5B). Co-injection of
uninfected human erythrocytes with dGAG-KI01 was com-
pared with injection of uninfected erythrocytes without
dGAG-KI01. No difference was seen, and the amount was
stable below 1% (unpublished data).
Rats were also treated with GAGs after the IE (FCR3S1.2)
had sequestered in order to study the capacity of the GAGs to
release IE into circulation. At 5-lg dGAG injected/animal,
sequestration was reduced by approximately 50%, and a
similar effect was seen at 50 lg (Figure 5C and Figure S3).
When standard heparin was injected, the sequestration
decreased somewhat less than after injection of dGAGs since
at 5-lg heparin/rat, sequestration was reduced by approx-
imately 30% (Figure 5D). The lower effect of heparin than of
dGAG could be due to the capacity of heparin to not only
bind to DBL1a, but also to AT, mediating the anticoagulant
activity. Further, during surgery for removal of the lungs, it
was observed that the blood did not coagulate as in dGAG-
treated animals. An injection of dextran sulfate, an unrelated
negatively charged, sulfated polysaccharide did not result in a
signiﬁcant reduction of the sequestration (Figure 5E). Mock
treatment of animals carrying bound IE with RPMI-1640 also
did not affect the sequestration (unpublished data).
Effect of dGAG on Sequestration of IE of Clinical Isolates in
Rats
The effect of dGAG-KI01 and dGAG-DFX-101 on seques-
tration of IE of three clinical isolates of Ugandan children
with severe malaria (UAS22, UAS29, and UAS31; for status of
parasites, see Table 2) was also studied in the rat model. Since
the material was limited, the experiments could be performed
only in duplicates and with fewer concentrations of the
dGAGs (5 lg injected/animal for blocking of sequestration,
and 5 and 50 lg injected/animal for de-sequestration). Two or
three control animals that did not receive any dGAG were
run in parallel during each experiment. Lung sequestration
was 1.8% for UAS22 (one experiment, two animals), 4.0% for
UAS29 (three experiments, six animals), and 10.5% for
UAS31 (one experiment, three animals) of the total amount
of material injected. Blocking of sequestration with 5 lg/
animal dGAG-KI01 or dGAG-DFX-101 resulted in a reduced
binding of the IE of all three isolates, but the levels of
inhibition varied between the isolates (Figure 6A and Figure
S3). Rats treated with dGAG-KI01 or dGAG-DFX-101 after the
IE had sequestered showed substantial reduction of seques-
tration when injected with 50 lg/animal, but with 5 lg/animal
1A
1B
Figure 1. Binding of dGAG-KI01 to P. falciparum Antigens
(A) dGAG-KI01 binding to DBL1a was analyzed using an in-solution assay.
A fixed concentration (4 lg/ml) was allowed to incubate with increasing
concentrations of
3H-dGAG-KI01. Protein with bound dGAG was
recovered by membrane filtration.
(B) Aliquots of rosetting parasite cultures (UAS22, UAS29, UAS31, and
FCR3S1.2) were incubated with
3H-dGAG-KI01. Cells were lysed in
hypotonic buffer, and membranes (M) were separated from the
supernatants (S).
3H-dGAG-KI01 bound to DBL1a and cell compartments
were analyzed by scintillation counting.
DOI: 10.1371/journal.ppat.0020100.g001
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Treatment of Severe Malariaof dGAGs, moderate effects on the sequestration were seen
(Figure 6B and Figure S3).
Sequestration of P. falciparum–Infected Erythrocytes in
Macaca fascicularis
A new animal model for the study of the sequestration of
human P. falciparum–infected erythrocytes in macaques (M.
fascicularis) was developed based on the rat model used herein
[33]. Brieﬂy, sedated macaques were administrated with
approximately 10
8 highly puriﬁed
99mTechnetium (
99mTc)-
labeled human uninfected erythrocytes or P. falciparum–
infected erythrocytes of the FCR3S1.2 clone by injection into
the Vena saphena magna. The animals were left for 30 min (time
point 30 min) to allow IE to sequester and thereafter either
kept untreated or treated with dGAG-DFX-101 and left for an
additional 30 min (time point 60 min). Macaques were in a
ﬁrst set of experiments examined for the identiﬁcation of
sites where sequestration occurred. At time point 30 min, one
of the animals (ID 5018) injected with IE (FCR3S1.2) showed
9.4% of the injected material in the lungs. At time point 60
min, the proportion of material in the lungs was 8.5% (ID
5018) and 8.7% (ID 2030, not measured at 30 min), indicating
sequestration in the lungs to be stable (Figure 7). Binding of
99mTc-labeled IE was also seen in the bone marrow of the
vertebrae and the humerus (Figure 7A). A total of 3.4% of the
material was detected in the lungs of an animal (ID 7020)
injected with
99mTc-labeled uninfected erythrocytes, and a
large fraction of the radioactivity was also found in the heart
and therefore in circulation (Figure 7). Taken together, this
indicates that speciﬁc sequestration of human IE occurs
primarily in the lungs of M. fascicularis as previously observed
in the rat [33].
Effect of dGAG on IE Sequestration in M. fascicularis
Three macaques (ID 8120, 9044, and 4044) were injected
with puriﬁed
99mTc-labeled IE of FCR3S1.2, and tomography
images were acquired before and after injection of the dGAG-
DFX-101 at time points 30 min and 60 min. dGAG-DFX-101
(500 lg) was injected into the animal after 30 min in a total
volume of 5-ml RPMI-1640 into the Vena saphena magna.
Images at time point 30 min (immediately prior to injection
of dGAG-DFX-101) revealed an average of 9.2% (9.8%, ID
8120; 9.1%, ID 9044; and 8.7 %, ID 4044) of the injected
material present in the lungs, a ﬁgure similar to that of the
control animal (see above, ID 5018). An average of 5.7% of
the injected IE (5.7%, ID 8120; 6.0%, ID 9044; and 5.5 %, ID
4044) was left in the lungs in dGAG-DFX-101–treated animals
at time point 60 min, 30 min after the injection of the dGAG-
DFX-101. The corresponding ﬁgure from the lungs of the
untreated animals injected with solely IE was 8.6% (see above,
ID 5018 and 2030) at time point 60 min. In order to
determine parasite speciﬁc sequestration of IE, the non-
speciﬁc, non-PfEMP1–mediated trapping of uninfected hu-
man erythrocytes (see above, 3.4%, ID 7020) was subtracted
from the amount of binding in the treated animals (5.7%, ID
8120; 6.0%, ID 9044; and 5.5 %, ID 4044) and in the untreated
controls (8.7%, ID 2030; and 8.5%, ID 5018). The reduction of
sequestration in the treated animals was then approximately
Figure 2. Effect of Heparin and HS on P. falciparum Rosettes and Cytoadherence of IE In Vitro
(A) Aliquots of rosetting parasite cultures (FCR3S1.2) were treated with heparin or HS at different concentrations. The rosetting-rates were counted after
30 min incubation and compared with mock treated samples. The cytoadherence assays (B and C) with IE (FCR3S1.2) and heparin or HS were performed
under orbital shaking (50 rpm) at 37 8C. Increasing concentrations of heparin and HS were added together with IE (B) or after letting the IE adhere (C).
Unbound material was removed before the slides were fixed in glutaraldehyde, stained with Giemsa and analyzed by light microscopy at a x1,000
magnification.
DOI: 10.1371/journal.ppat.0020100.g002
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Treatment of Severe Malaria55% (56%, ID 8120; 50%, ID 9044; and 60%, ID 4044) when
compared to untreated controls (Figure 8A). Differences in
bone marrow sequestration were not sufﬁciently robust to be
evaluated for differences between treated or untreated
animals. One monkey (ID 7020) injected with
99mTc-labeled
IE of FCR3S1.2 was analyzed by dynamically monitoring the
levels of sequestration using a two-dimensional gamma
camera and X-ray before and during the treatment (unpub-
lished data). The proportion of injected material present in
the lungs over time showed a series of ﬂuctuations directly
after the injection of dGAG-DFX-101. Thereafter the lung-
sequestration dropped and was stabilized at the lower level
(unpublished data).
The number of
99mTc-labeled IE in circulation was in all
cases found to be low (,2% of injected material) as analyzed
by studying the levels of
99mTc-labeled IE in the heart prior to
treatment (time point 30 min). However, after injection of
dGAG-DFX-101 (time point 60 min), the circulating IE
increased by an average of 13% (9%, ID 8120; 30%, ID
9044; and 0%, ID 4044; Figure 8B). In contrast, the amount of
material present in the heart in one animal injected with IE,
but left untreated, decreased by 22% (ID 5018; Figure 8B),
suggesting the IE sequestration to have increased with time.
Discussion
Here we report the generation of dGAGs for their use as
adjunct treatment in patients with severe malaria. The
dGAGs are derived from standard heparin; they lack anti-
coagulant activity, block merozoite invasion of erythrocytes,
disrupt rosettes, inhibit endothelial binding in vitro, and
reverse sequestration in in vivo models of severe malaria. The
data suggest that the dGAGs may be useful in the treatment of
Figure 4. Effects of Different GAGs on Reinvasion of P. falciparum
Merozoites (FCR3S1.2) into Fresh Erythrocytes In Vitro
Parasite culture at throphozoite stage (’25 h of development) at a 0.4%
parasitemia and a 2% hematocrit were incubated with increasing
concentrations of dGAG-KI01, heparin, CSA, or HA for 24–30 h at 37 8C.
Parasitemias were estimated using FACS counting with a minimum of
50,000 cells per sample.
DOI: 10.1371/journal.ppat.0020100.g004
3A 3C
3B
Figure 3. Effect of dGAG-KI01 on P. falciparum Rosettes and Cytoadherence of IE In Vitro
(A) Aliquots of rosetting parasite cultures (UAS22, UAS29, UAS31, and FCR3S1.2) were treated with dGAG-KI01 at different concentrations. The rosetting
rates were counted after 30-min incubation and compared with mock-treated samples.
(B) and (C) For the cytoadherence assays, different P. falciparum IE (UAS22, UAS29, UAS31, and FCR3S1.2) were allowed to attach to rat lung sections
under orbital shaking (50 rpm) at 37 8C. Different concentrations of dGAG-KI01 were added together with IE (B) or after letting the IE adhere
(C). Unbound material was removed by washes before the slides were fixed in glutaraldehyde, stained with Giemsa, and analyzed by light microscopy at
a 1,0003 magnification.
DOI: 10.1371/journal.ppat.0020100.g003
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Treatment of Severe Malariasevere human malaria and that the previously observed effect
of heparin on cerebral malaria [22–26] is likely to depend on
the antisequestration activity rather than the anticoagulant
activity of heparin.
A major obstacle in the development of drugs aiming at
reducing severe malaria pathology has been the lack of robust
animal models for screening and evaluating drug candidates.
We have therefore recently developed an in vivo model in
which the sequestration (cytoadherence and rosetting) of
human IE can be monitored for a short period in the rat [33].
The technique has here been further adapted for the use in
macaque monkeys (M. fascicularis) which are intra-venously
injected with
99mTc-labeled human IE and then evaluated for
sequestration by using a three headed gamma camera and X-
ray for imaging, rendering three-dimensional information on
both the distribution of the radioisotope and the anatomy of
the animal (Figure 7). The technique makes it possible to
avoid euthanasia while still allowing the acquisition of
reliable data on the level of the sequestration of IE in vivo.
The adhesion of the IE has been shown to depend on PfEMP1
in both rats and macaques by (1) vaccinating the animals with
the DBL1a domain, the HS-binding fragment of PfEMP1
[33,34] (K. Moll, F. Pettersson, A. M. Vogt, C. Jonsson, N. Rasti,
S. Ahuja, M. Spa ˚ngberg, P. Bull, O. Mercereau-Puijalon, D. E.
Arnot, M. Wahlgren, and Q. Chen, unpublished data),
whereby the sequestration of the IE is inhibited, or by (2)
Figure 5. Injection of dGAG-KI01 into Rats Prevents Sequestration of P. falciparum (FCR3S1.2) IE in the Lungs
(A) and (B) Rats received either
99mTc-labeled IE simultaneously with different concentrations of the dGAG-KI01 (sequestration blocking) (A), or were first
injected with
99mTc-labeled IE and, after three min, injected with dGAG-KI01 (de-sequestration) (B).
(C) Whole-body summary images of rats captured 21–30 min after the injection of
99mTc-labeled IE alone ( dGAG-KI01) or when co-injected with 5 lgo f
dGAG-KI01 (þdGAG-KI01).
(D) and (E) Rats were injected with
99mTc-labeled IE and subsequently with heparin (D) or the sulfated polysaccharide dextran sulfate (E).
Rats were in all cases left in the gamma camera for 30 min after which the lungs were excised, measured for radioactivity, and compared to the level of
radioactivity in the whole animal. Results are presented as relative amount in lungs compared with control animals receiving no dGAG-KI01, heparin, or
dextran sulfate (control, adjusted to 100%; grey bars). White bars show the results of individual rats, and striped bars, the mean thereof.
DOI: 10.1371/journal.ppat.0020100.g005
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Treatment of Severe Malariathe treatment of the animals with a PfEMP1-adhesion
receptor analog [33] as also shown herein. The receptors
employed by the IE of different isolates (multiadhesive, HS,
CSA, CD36, or CD31 binding) have been carefully charac-
terized in vitro [33]. The majority of the injected human
erythrocytes are, however, regardless of being infected or not,
absorbed by the liver, spleen, and kidneys. This reﬂects the
incompatibility between the human erythrocytes and the
animals, resulting in the presumably non-speciﬁc removal of
injected material by tissue macrophages. Still, the capacity of
IE to robustly adhere in the lungs of both animal species
argues that these two animal models are new useful additions
for the screening of antiplasmodial drugs and vaccines.
The rat model allows measurement of sequestration of
human IE in the lungs of immunocompetent animals.
Sequestration in the rat represents rosetting, autoagglutina-
tion, and cytoadherence [33], which is why any decrease of
sequestration is likely to be a consequence of inhibition and
disruption of all these adhesive events. The effect on
clumping of IE with platelets is less clear. Sequestration-
blocking and de-sequestration activities of the dGAGs were
observed in rats both with a cloned parasite and with wild
isolates, although the levels of inhibition varied somewhat.
Blocking of sequestration of a cloned parasite gave a
maximum effect with an intermediate quantity of dGAG-
KI01, whereas higher (and lower) amounts resulted in lesser
effects (Figure 5A). This trend was not as obvious while
evaluating de-sequestration of the same cloned parasite in
vivo (Figure 5B). The lesser response to the higher quantities
of dGAGs injected might be a consequence of cross-binding
between dGAG-binding molecules present on the rat endo-
thelium, the dGAG, and the IE. Similarly, a somewhat lesser
effect was also seen while inhibiting cytoadherence on rat
lung sections in vitro and analyzing high concentrations of
heparin and HS (Figure 3B and 3C), but this effect has not
been seen with primary human endothelial cells [19].
De-sequestration by dGAG treatment was further studied
in the monkeys 30 min after they had been injected with IE,
when the level of sequestration was stable. Each monkey was
treated with 500 lg of dGAG, resulting in a reduction of
sequestration of up to 60% when comparing treated with
untreated animals (Figure 8A). The effect of the dGAG on
sequestration was also studied by dynamically monitoring the
level of radioactive material present in the lungs before and
during the treatment in one monkey (unpublished data). The
results demonstrate two interesting ﬁndings: an increase in
pulmonary-available parasites directly following the injection
of dGAG and a later decrease in sequestration at about 10
min after the injection. The initial ﬂuctuation may be the
result of a release of previously sequestered IE from different
sites in the body, resulting in a short period of elevated levels
of circulating IE passing through the lungs. This interpreta-
tion is supported by the ﬁnding that the radioactive material
in the heart is increased in animals injected with dGAG as
compared to a reduction seen in non-treated animals (Figure
8B).
Table 2. Rosetting Rates and Number of Generation of In Vitro
Growth of Parasites Used in the Animal Experiments
Parasite Experiment Generations
a Rosetting Rate (%)
FCR3S1.2 KI01 in rats NA
b 76–90
Dextran sulfate in rats NA
b 84
DFX-101 in rats NA
b 83
DFX-101 in monkeys NA
b 85
UAS22 KI01 in rats 22 57
DFX-101 in rats 22 57
UAS29 KI01 in rats (5 lg/animal) 5 60
KI01 in rats (50 lg/animal) 10 85
DFX-101 in rats 19 65
UAS31 KI01 in rats 6 67
DFX-101 in rats 6 67
aNumber of generations of in vitro growth of fresh isolates.
bNA, not applicable, FCR3S1.2 is a clonal, long-term propagated parasite [41].
DOI: 10.1371/journal.ppat.0020100.t002
Figure 6. Injection of dGAG-KI01 Decreases P. falciparum Sequestration
of IE of Clinical Isolates in the Rat
(A) Rats were co-injected with
99mTc-labeled IE (clinical isolates: UAS22,
UAS29, and UAS31) and 5 lg of the dGAG-KI01, or (B) rats were first
administrated with
99mTc-labeled IE (clinical isolates: UAS22, UAS29, and
UAS31) and after 3 min, injected with different concentrations of the
dGAG-KI01. Rats were in all cases left in the gamma camera for 30 min,
after which the lungs were excised, measured for radioactivity, and
compared to the level of radioactivity in the whole animal. Results are
presented as relative amount in lungs compared with control animal
receiving no dGAG-KI01 (control, adjusted to 100%; grey bars). White
bars show the results of individual rats, and the striped bars, the mean
thereof.
DOI: 10.1371/journal.ppat.0020100.g006
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Treatment of Severe MalariaBased on the assumption that disseminated intravascular
coagulation is a central mechanism in malaria pathogenesis,
anticoagulant therapy with heparin was previously used with
some success in the treatment of human cerebral malaria [22–
26]. The use of heparin was later abandoned due to the
occurrence of severe bleedings and death of some children
treated [27]. However, a better knowledge of the sequestra-
tion mechanisms causing severe malaria, and recent data
suggesting an important role for HS as an IE-adhesion
receptor prompted us to develop novel antisequestration
compounds based on heparin. The use of CSA has previously
been considered for adjunct treatment of malaria [35], but
parasites speciﬁc for CSA are mainly found in pregnant
women and not in children or adults with cerebral malaria or
respiratory distress. We therefore developed heparin analogs
chemically depleted of anticoagulant activity, dGAGs, and
7A
7B
Figure 7. Sequestration of P. falciparum IE of Parasite FCR3S1.2 in
Macaca fascicularis
Monkeys were injected with
99mTc-labeled IE of FCR3S1.2 or with
99mTc-
labeled uninfected human erythrocytes and left for 60 min followed by
analysis in an X-ray–equipped triple-headed gamma camera (ID 7020,
uninfected erythrocytes; ID 2030 and 5018, IE).
(A) Shows the whole-body summary images captured 60–75 min after
the injection of the
99mTc-labeled cells. Amplified areas show the chest
cavities and the vertebrae. The accumulation of
99mTc-labeled IE in the
lungs and in the bone marrow suggests their specific sequestration. The
activity in the heart of the animal that received uninfected erythrocytes
indicates that the erythrocytes are in circulation.
(B) Shows the relative amount of material in the lungs as compared with
the activity of the whole animal and measured for 15 min (60 to 75 min
after injection). White bars show results of individual monkeys injected
with IE, whereas the grey bars show the results of the control animal
injected with uninfected human erythrocytes.
DOI: 10.1371/journal.ppat.0020100.g007
Figure 8. Injection of dGAG-DFX-101 Releases Sequestered P. falciparum
IE into Circulation in M. fascicularis
Five macaques (M. fascicularis) were injected with
99mTc-labeled IE of the
parasite FCR3S1.2 and left for 30 min. Three of the monkeys (ID 8120,
9044, and 4044) each received 500-lg dGAG-DFX-101 by intravenous
injection while two monkeys (ID 2030 and 5018) were left untreated.
(A) Shows the level of material in the lungs. The dGAG was injected at
time point 30 min and the radioactivity in the animals were measured for
15 min 60 to 75 min after injection. The level of radioactive material in
the lungs was compared with the amount of radioactive material in the
whole animal. Results are presented as relative amount in lungs
compared with control animal receiving no dGAG-DFX-101 (control,
adjusted to 100%; grey bar). White bars show the relative amount of
material in individual monkeys, and the striped bars, the mean thereof.
(B) Shows the level of material in the hearts before and after the injection
of the dGAG-DFX-101. The radioactive material in the hearts (i.e., in
circulation) increases (9%, ID 8120; 30% ID 9044; and 0% ID 4044) after
treatment with dGAG-DFX-101. In contrast, the amount of material in the
heart of the monkey left untreated decreased by 22% (ID 5018). The
analysis of the radioactivity in the hearts was performed by comparing
amounts of material present at time point 30 min and at time point 60
min, after the dGAG-DFX-101 was injected. Time point 30 min was
adjusted to 100%. The arrow shows the time point of injection of the
dGAG-DFX-101.
DOI: 10.1371/journal.ppat.0020100.g008
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Treatment of Severe Malariashow here that IE sequestration can be disrupted and that the
de-sequestered IE are released into circulation by the
injection of dGAGs. Besides the antisequestration properties,
dGAGs may affect disease development by limiting the
growth of parasites because dGAG inhibits merozoite
invasion into fresh erythrocytes in vitro (Figure 4).
The observed effects of dGAG on sequestration probably
represent not only true de-sequestration, but also blocking of
initial and continued adhesion of IE that are still available in
the circulation. This kind of treatment may not release 100%
of the sequestered IE, although even partial de-sequestration
may have an impact of the development of the disease. The
sequestration of IE of some clinical P. falciparum isolates
analyzed was more susceptible to the dGAGs than the
sequestration of IE of other isolates. This is in concordance
with previously observed differences of the dependency of HS
for cytoadherence and rosetting [2,19,36]. The effects on
sequestration, although sometimes relatively small, are still
likely to be of fundamental importance to re-establish the
circulation in the affected vasculature. The results from our
in vivo experiments in rats present a therapeutic window
approximately between 1–100 lg/kg, but a dose for future use
in patients has to be additionally discussed and decided in
view of previous human studies of heparin when used for
treating severe malaria or other disease states.
The strategy of development of the dGAGs described here
has yielded an effective treatment of severe malaria in two
animal models. Because heparin is an endogenous molecule
expressed in mast cells, immune responses are not expected
to be elicited by heparin or by dGAGs, but this has to be
further investigated in safety and toxicology tests. Future
plans also include the development of cost-effective and
stable large-scale production protocols and preclinical test-
ing in animals and humans. If this approach is successfully
translated to the clinical setting, it may offer help to patients
whereby the injection of dGAGs releases already sequestered
parasite-infected erythrocytes and re-establishes the micro-
vascular blood ﬂow. We suggest dGAGs to be promising
candidates of adjunct therapy that may have an impact on
malaria mortality. Taken together, the results presented here
support the evaluation of the dGAGs as adjunct therapy in
severe malaria for an impact on the mortality from this severe
disease state.
Materials and Methods
Generation and
3H-labeling of dGAGs. For the generation of
heparin lacking anticoagulant activity, dGAG, the AT binding
sequence within heparin was oxidized by the use of periodate, as
previously described [29]. Brieﬂy, 2-mg/ml heparin (Lo ¨vens Kemiske
Fabrik, Ballerup, Denmark) was incubated in 50 mmol/l sodium
citrate, 0.2 mol/l NaClO4 and 20 mmol/l NaIO4 (pH 3), at 4 8C for 2 h
(KI01). The reaction was stopped by extensively dialyzing the samples
against H2O. NaBH4 (20-mg/mg heparin in 1-ml H2O) was added to
the solution and incubated for an additional 3 h at room temperature
(RT) and dialyzed against H2O. A second dGAG batch (DFX-101) was
produced in a similar manner under Good Manufacturing Practice
(GMP) conditions. The preparations were freeze-dried. An aliquot of
the dGAG-KI01 preparation was labeled with
3H by reduction with
NaB
3H, as previously described [37].
Quantity and quality analysis of dGAGs. Concentrations of ﬁnal
dGAG preparations were determined as previously described [38],
and the speciﬁc activity of
3H-labeled KI01 was found to be 25,800
cpm/lg. The anticoagulant activity of dGAGs was tested using the
APTT test Cephotest (Nycomed AB, Lidingo ¨, Sweden). Brieﬂy, 190 ll
of human plasma mixed with different GAG preparations and 200 ll
Cephotest reagent was pre-incubated for 5 min at 37 8C before
adding CaCl2 to a ﬁnal concentration of 6.7 mmol/l. Upon addition of
Ca
2þ, the time was measured until clots were formed. The different
dGAG preparations were compared with un-fractionated (standard)
heparin, high and low AT–afﬁnity heparin generated as described
[32], and phosphate buffered saline (PBS) as negative control.
dGAG binding to recombinant DBL1a protein and to live IE. An in-
solution binding assay of
3H-labeled dGAG-KI01 to DBL1a, cloned
from FCR3S1.2, was carried out as described [39]. In brief, 4 lg of the
recombinant fusion protein DBL1a-GST [40] or GST were incubated
with different concentrations of
3H-labeled dGAG-KI01 in 200 ll5 0
mmol/l Tris [pH 7.4], 150 mmol/l NaCl, and 0.1% BSA in duplicates
for 1 h at RT. The samples were then trapped on a nitrocellulose ﬁlter
(pore size 0.45 lm) and washed. Bound radioactive material was
eluted with 2 mol/l NaCl and quantiﬁed by scintillation counting. The
interaction between dGAG-KI01 and live IE was carried out by
incubating IE (1310
8) with 0.9-lg
3H-labeled dGAG-KI01in RPMI for
30 min at RT with constant careful mixing. After three washes in
RPMI, cells were lysed in 1 mM Tris [pH 7.4], supplemented with 0.1
mM EDTA. Samples were centrifuged, membranes were separated
from supernatants, and the radioactivity was analyzed by liquid
scintillation counting.
The parasites. The highly rosetting and autoagglutinating parasite
FCR3S1.2 was obtained through cloning by micromanipulation of
FCR3S1 [34]. It was cultured according to standard methods using
candle jar technique [40], and the rosetting rate was kept at .75% by
centrifugation on Ficoll-Paque as previously described [41]. The P.
falciparum clinical isolates UAS22, UAS29, and UAS31 were obtained
from children with severe malaria from Apac, Uganda (ethical
permission 03/095). Informed consent was obtained from the patients
and/or their guardians, 2–5 ml of venous blood was taken, and the
erythrocytes were separated from the leukocytes by centrifugation on
Lymphoprep (Nycomed) as described elsewhere [4] and frozen
according to standard procedures [40]. For the assays, frozen blood
samples were maintained and expanded in O Rh
þ erythrocytes at 5%
hematocrit with 15% AB
þhuman serum added to the malaria culture
medium (MCM; RPMI-1604 supplemented with HEPES, gentamycin,
and sodium bicarbonate). Gas was used to maintain a low oxygen
pressure during cultivation (5% O2,5 %C O 2, and 90% NO2; AGA,
Lidingo ¨, Sweden).
Rosetting and cytoadherence disruption assays in vitro. The
rosetting-disruption assays with dGAGs and GAGs (heparin and HS
[Lo ¨vens Kemiske Fabrik]) were performed essentially as previously
described [36]. The effect of dGAG or GAGs (heparin and HS) on
cytoadherence was tested using magnet-enriched IE [42], and
cryosections of rat lungs as previously described [33]. IE were either
added together with the dGAG to the lung sections and incubated for
30 min at 37 8C following three careful washes, or added solely to the
section and allowed to adhere for 30 min at 37 8C before careful
washing three times, whereafter the sections were incubated with
dGAG for another 30 min at 37 8C followed by a ﬁnal three washes.
All washes were with RPMI-1640, and the concentrations of dGAG
were as stated in the text. In both setups, samples were incubated with
orbital shaking of the samples (50 rpm), and the sections were ﬁxed in
1% glutaraldehyde (Sigma, St. Louis, Missouri, United States) in PBS
at RT for 30 min before staining with Giemsa. The ﬁxed and stained
sections were analyzed in light microscopy (Nikon Optiphot, Tokyo,
Japan) by counting the number of bound IE in four parallel lanes
from the top to the bottom and four parallel lanes from the left to the
right.
Merozoite invasion inhibition assay in vitro. The merozoite
invasion inhibition assay with dGAGs (KI01 and DFX-101) and GAGs
(heparin [Lo ¨vens Kemiske Fabrik], CSA (bovinel Fluka, Buchs,
Switzerland) and HA (Streptococcus equi sp.; Fluka) was essentially
performed as previously described [32]. Brieﬂy, trophozoite-
synchronized P. falciparum cultures with a parasitemia of 0.4% and
a hematocrit of 2% were grown in MCM in micro-cultures (100 ll) in
the presence of increasing concentrations of dGAG or GAGs at 37 8C
for 24–30 h. In order to quantify the parasitemia, the samples were
stained for 10 s with acridine orange and then analyzed using a FACS
instrument from Becton Dickinson (Mountain View, California,
United States). A minimum of 50,000 cells per sample were collected.
In vivo studies of sequestration in rats. Sprague Dawley rats (male,
3–6 mo old, and an approximate mean weight of 500 g; B&K,
Sollentuna, Sweden) were kept in the animal facility of the Swedish
Institute for Infectious Disease Control (SMI). P. falciparum–infected
human erythrocytes were cultivated in vitro and enriched to a
parasitemia above 70%. Prior to injection into the animals, the same
number of human infected or uninfected erythrocytes were washed
in RPMI and radioactively labeled with
99mTc in parallel as previously
PLoS Pathogens | www.plospathogens.org September 2006 | Volume 2 | Issue 9 | e100 0861
Treatment of Severe Malariadescribed [33]. Rats were anaesthetized with Dormicum (Roche, Basel,
Switzerland), Hypnorm (Janssen Pharm Centica, Beerse, Belgium),
and H2O (1:1:2) and 0.8–2.7 3 10
7 IE or uninfected erythrocytes, in
0.5-ml RPMI-1640, were injected intravenously into the tail vein. The
treated rats were either co-injected with IE and different concen-
trations of the dGAG, or ﬁrst injected with IE and, after 3 min,
injected with different concentration of dGAG, heparin, or dextran
sulfate (Leuconostoc spp.; Sigma) in 0.5-ml RPMI-1640, whereas control
animals were injected with IE without dGAG, heparin, or dextran
sulfate. The distribution of the labeled cells was monitored using a
gamma camera for 30 min as previously described [33]. The relative
amount of labeled cells sequestered in the lungs was calculated by
comparing the activity of excised lungs to that of the whole animal.
All the experiments were carried out with appropriate ethical
permissions (N177/01, N178/01, N176/03, and N184/05).
In vivo studies of sequestration in M. fascicularis. The primate
model for the study of the sequestration of P. falciparum infected
human erythrocytes in macaques (M. fascicularis) was developed based
on the rat model used herein [37]. Six female macaques (ID 5018,
2030, 8120, 9044, 4044, and 7020) were kept in the animal facility of
SMI. The animals were sedated with Ketaminol Vet (Farmaceutici
Gellini S.p.A, Aprilia, Italy) and during the challenge kept asleep with
a combination of Ketaminol Vet and Rompun Vet (Bayer AB,
Gothenburg, Sweden). Uninfected human erythrocytes or highly
puriﬁed IE (.80% parasitemia) of the FCR3S1.2 clone were radio-
actively labeled with
99mTc prior to injection into the animals as
previously described [33]. Approximately 10
8 cells were administrated
by a 1-min injection of a 5-ml sample of cells diluted in RPMI-1640,
into the Vena saphena magna, and the animals were left for 30 min to
let the IE sequester. Four of the animals injected with IE (ID 8120,
9044, 4044, and 7020) were subsequently injected with 500-lg dGAG-
DFX-101 per animal, diluted in 5-ml RPMI-1640, into the Vena saphena
magna during 1 min, while two animals injected with IE (ID 5018 and
2030) and one animal injected with uninfected human erythrocytes
(ID 7020) were left without additional injections. All animals, treated
or untreated, were left for another 30 min. Six (ID 5018, 8120, 9044,
4044, 7020, and 2030) animals examined were analyzed by whole-body
imaging in an X-ray instrument equipped with a triple-headed
gamma camera allowing for three-dimensional reconstruction, both
on the anatomy and the radioisotope distribution (TRIAD XLT;
Trionix Research Lab, Twinsburg, Ohio, United States) of the
pictures showing the anatomy of the animal as well as the number
of counts in speciﬁc body volumes. The amount of injected material
ending up in different organs could hence be accurately determined
by careful mapping of the organs using the X-ray image and imposing
this map on the image showing the radioisotope distribution. Animals
analyzed with this three-dimensional reconstruction were either
analyzed in the camera after 30 min and after 60 min, or only after 60
min. One animal injected with IE and treated with dGAG (ID 7020)
was analyzed dynamically with a two-dimensional technique [33] for
60 min. This technique does not allow measurement of the activity in
parts covered by other organs, and the absolute ﬁgures are not
comparable to those acquired by tomography (three-dimensional
reconstruction). After being analyzed, animals were brought back to
the animal facility and kept under observation. No signs of any
disorders of the animals were observed. All the experiments were
carried out with appropriate ethical permissions (N308/04 and N183/
05).
Statistical analyses. Where applicable, data are presented as mean
6 standard deviation.
Supporting Information
Figure S1. Effect of dGAG-DFX-101 on P. falciparum Rosettes and
Cytoadherence of IE In Vitro
(A) Aliquots of rosetting cultures (UAS22, UAS29, UAS31, and
FCR3S1.2) were treated with dGAG-DFX-101 at different concen-
trations. The rosetting rates were counted after 30 min incubation
and compared with mock-treated samples. For the cytoadherence
assays (B) and (C), the IE of different P. falciparum cultures (UAS22,
UAS29, UAS31, and FCR3S1.2) were allowed to attach to rat lung
sections under orbital shaking (50 rpm) at 37 8C. Different
concentrations of dGAG-DFX-101 were added together with IE (B)
or after letting the IE adhere (C). Unbound material was removed by
washes before the slides were ﬁxed in 1 % glutaraldehyde, stained
with Giemsa, and analyzed by light microscopy at a 1,0003
magniﬁcation.
Found at DOI: 10.1371/journal.ppat.0020100.sg001 (34 KB PDF).
Figure S2. Effects of dGAG-DFX-101 on Reinvasion of P. falciparum
Merozoites (FCR3S1.2) into Fresh Erythrocytes In Vitro
Parasite culture at throphozoite stage (’25 h of development) with a
0.4% parasitemia and a 2% hematocrit were incubated with
increasing concentrations of dGAG-DFX-101 for 24–30 h at 37 8C.
Levels of parasitemias were estimated using FACS counting a
minimum of 50,000 cells per sample.
Found at DOI: 10.1371/journal.ppat.0020100.sg002 (27 KB PDF).
Figure S3. Injection of dGAG-DFX-101 Reduces Sequestration of P.
falciparum IE in Rats
(A) Rats previously administrated with
99mTc-labeled IE of parasite
FCR3S1.2 were injected with different concentrations of dGAG-DFX-
101 for measurement of the de-sequestration effect. (B)
99mTc-labeled
IE of the UAS isolates (UAS22, UAS29, and UAS31) were adminis-
trated to rats simultaneously with 5 lg of the dGAG-DFX-101,
whereas in (C), the de-sequestration effects of different concen-
trations of dGAG-DFX-101 was tested by injection of dGAG-DFX-101
3 min after the injection of IE. Rats were in all cases left in the gamma
camera for 30 min after which the lungs were excised, measured for
radioactivity, and compared to the radioactive material found in the
whole animal. Results are presented as relative amount in lungs
compared with control animal receiving no dGAG-DFX-101 (control,
adjusted to 100%; grey bars). White bars show radioactivity in
individual rats, and striped bars, the means thereof.
Found at DOI: 10.1371/journal.ppat.0020100.sg003 (55 KB PDF).
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